Is It Time for Costco to Split?
Costco’s stock price has experienced enormous growth over the last…
Sell
46
JAZZ Quote, Financials, Valuation and Earnings
Last price:
$123.09
Seasonality move
:
4.86%
Day range:
$121.96 - $124.60
52-week range:
$99.06 - $134.17
Dividend yield:
0%
P/E ratio:
17.32x
P/S ratio:
2.04x
P/B ratio:
1.78x
Volume:
463.5K
Avg. volume:
603.1K
1-year change:
-0.02%
Market cap:
$7.4B
Revenue:
$3.8B
EPS (TTM):
$7.10
Analysts' Opinion
-
Consensus RatingJazz Pharmaceuticals PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $181.05, Jazz Pharmaceuticals PLC has an estimated upside of 47.23% from its current price of $122.97.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $128.00 representing 100% downside risk from its current price of $122.97.
Fair Value
-
According to the consensus of 11 analysts, Jazz Pharmaceuticals PLC has 47.23% upside to fair value with a price target of $181.05 per share.
JAZZ vs. S&P 500
-
Over the past 5 trading days, Jazz Pharmaceuticals PLC has overperformed the S&P 500 by 2.25% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Jazz Pharmaceuticals PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Jazz Pharmaceuticals PLC has grown year-over-year revenues for 64 quarters straight. In the most recent quarter Jazz Pharmaceuticals PLC reported revenues of $1.1B.
Earnings Growth
-
Jazz Pharmaceuticals PLC has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Jazz Pharmaceuticals PLC reported earnings per share of $3.42.
Enterprise value:
10.9B
EV / Invested capital:
--
Price / LTM sales:
2.04x
EV / EBIT:
16.66x
EV / Revenue:
2.74x
PEG ratio (5yr expected):
0.02x
EV / Free cash flow:
9.92x
Price / Operating cash flow:
7.39x
Enterprise value / EBITDA:
8.36x
Gross Profit (TTM):
$3.6B
Return On Assets:
4.03%
Net Income Margin (TTM):
11.6%
Return On Equity:
12.28%
Return On Invested Capital:
4.84%
Operating Margin:
24.67%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $3.6B | $3.8B | $4B | $972.1M | $1.1B | |
| Gross Profit | $3.1B | $3.3B | $3.6B | $870M | $943.4M | |
| Operating Income | $450M | $568.7M | $676.4M | $172.4M | $260.2M | |
| EBITDA | $874.5M | $813.9M | $1.3B | $333.6M | $424.7M | |
| Diluted EPS | -$0.30 | $0.88 | $7.10 | $2.14 | $3.42 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.6B | $2.6B | $2.6B | $3.2B | $4.4B | |
| Total Assets | $6.3B | $12.5B | $10.4B | $11.2B | $12.3B | |
| Current Liabilities | $642.1M | $735.1M | $813M | $1.6B | $1B | |
| Total Liabilities | $2.9B | $8.5B | $7.6B | $7.7B | $8.1B | |
| Total Equity | $3.4B | $3.9B | $2.7B | $3.5B | $4.2B | |
| Total Debt | $2.1B | $6.3B | $5.7B | $5.7B | $6.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.1B | $1.3B | $1.2B | $307.2M | $398.7M | |
| Cash From Investing | -$131.9M | -$589.2M | -$213.1M | -$174.3M | $214.1M | |
| Cash From Financing | -$795.7M | -$185.4M | -$71.5M | -$78.5M | $246.4M | |
| Free Cash Flow | $984M | $867.4M | $1.1B | $302.9M | $388M | |
JAZZ
Sector
Market Cap
$7.4B
$46.3M
Price % of 52-Week High
91.65%
46%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.64%
1-Year Price Total Return
-0.02%
-33.33%
Beta (5-Year)
0.568
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$123.62
200-day SMA
Buy
Level
$112.92
Bollinger Bands (100)
Buy
Level
108.81 - 121.57
Chaikin Money Flow
Buy
Level
13.7M
20-day SMA
Buy
Level
$122.87
Relative Strength Index (RSI14)
Buy
Level
51.82
ADX Line
Sell
Level
21.29
Williams %R
Neutral
Level
-44.3787
50-day SMA
Buy
Level
$119.69
MACD (12, 26)
Buy
Level
1.11
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
196.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.4147)
Sell
CA Score
(Annual)
Level (-0.9783)
Buy
Beneish M-Score
(Annual)
Level (-2.7113)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.5992)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Stock Forecast FAQ
In the current month, JAZZ has received 8 Buy ratings 3 Hold ratings, and 0 Sell ratings. The JAZZ average analyst price target in the past 3 months is $181.05.
-
Where Will Jazz Pharmaceuticals PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Jazz Pharmaceuticals PLC share price will rise to $181.05 per share over the next 12 months.
-
What Do Analysts Say About Jazz Pharmaceuticals PLC?
Analysts are divided on their view about Jazz Pharmaceuticals PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Jazz Pharmaceuticals PLC is a Sell and believe this share price will drop from its current level to $128.00.
-
What Is Jazz Pharmaceuticals PLC's Price Target?
The price target for Jazz Pharmaceuticals PLC over the next 1-year time period is forecast to be $181.05 according to 11 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is JAZZ A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Jazz Pharmaceuticals PLC is a Buy. 8 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of JAZZ?
You can purchase shares of Jazz Pharmaceuticals PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Jazz Pharmaceuticals PLC shares.
-
What Is The Jazz Pharmaceuticals PLC Share Price Today?
Jazz Pharmaceuticals PLC was last trading at $123.09 per share. This represents the most recent stock quote for Jazz Pharmaceuticals PLC. Yesterday, Jazz Pharmaceuticals PLC closed at $122.97 per share.
-
How To Buy Jazz Pharmaceuticals PLC Stock Online?
In order to purchase Jazz Pharmaceuticals PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FedEx’s Spinoff Boost Its Stock Price?
In a pre-holiday surprise announcement, management at FedEx (NYSE:FDX) released…
Why Is Buffett Buying Verisign?
Warren Buffett has spent 2024 stockpiling cash, even going so…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 41x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Buy
100
IPX alert for Dec 31
IperionX [IPX] is down 9.31% over the past day.
Buy
58
QMCO alert for Dec 31
Quantum [QMCO] is down 13.43% over the past day.
Buy
55
SMLR alert for Dec 31
Semler Scientific [SMLR] is down 4.39% over the past day.
